» Articles » PMID: 8720715

Cross-matches on Donor Cadaver Retinal Pigment Epithelial Cells in Corneal Risk Patients

Overview
Specialty Ophthalmology
Date 1996 Mar 1
PMID 8720715
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Allografts can be rejected either through the antibody-mediated or cellular pathways. The objective of this study was to look at the extent of antibody formation in patients awaiting re-keratoplasty using cross-matches on cadaver retinal pigment epithelial (RPE) cells.

Methods: Cadaver RPE cells were derived by trypsin digestion from donor eyes (n = 1200). After 3 days of cell cultivation, the cells were adherent and began to lose their pigment. By day 7 most cells were clear and grew as a polygonal monolayer. MHC class I expression by RPE cells was studied by the W6/32 (anti-HLA-A, B, C) monoclonal antibody (MoAb) and that of class II (HLA-DR) by the 136 MoAb. Normal RPE cells express few class I and no detectable class II antigens. For the induction of MHC expression, cells were subsequently stimulated with 250 U/ml of recombinant gamma-interferon for 5 days. Cells were used for tissue typing and also for cross-matches with recipient serum. Cross-matches were subsequently performed and measured by flow cytometry.

Results: Both class I and class II antigens were strongly enhanced, as could be shown by immunohistochemical staining. Some 20% of those patients awaiting rekeratoplasty (n = 60) were positive for anti-HLA antibodies. In one case anti-DR3 antibodies were detected in a recipient who had had several rejection episodes after keratoplasty.

Conclusions: RPE cells are not only useful for cadaver post-mortem HLA typing but also for donor-specific cross-matches. The degree of antibody formation after keratoplasty in rejecting patients was, however, low. This may imply that anti-HLA antibodies are not the major cause of corneal graft loss after keratoplasty.

Citing Articles

Solid phase-based cross-matching for solid organ transplantation: Currently out-of-stock but urgently required for improved allograft outcome.

Schlaf G, Bau D, Horstmann N, Sawers G, Altermann W Histol Histopathol. 2020; 35(9):937-948.

PMID: 32293696 DOI: 10.14670/HH-18-217.


ELISA-Based Crossmatching Allowing the Detection of Emerging Donor-Specific Anti-HLA Antibodies through the Use of Stored Donors' Cell Lysates.

Schlaf G, Stohr K, Rothhoff A, Altermann W Case Rep Transplant. 2015; 2015:763157.

PMID: 26634169 PMC: 4655030. DOI: 10.1155/2015/763157.


Solid phase-based cross-matching as solution for kidney allograft recipients pretreated with therapeutic antibodies.

Schlaf G, Apel S, Wahle A, Altermann W Biomed Res Int. 2015; 2015:587158.

PMID: 25654115 PMC: 4310493. DOI: 10.1155/2015/587158.


[Ranking of systemic steroids after normal-risk keratoplasty. Results of a randomized prospective study].

Mayweg S, Reinhard T, Spelsberg H, Reis A, Godehardt E, Sundmacher R Ophthalmologe. 2005; 102(5):497-501.

PMID: 15657693 DOI: 10.1007/s00347-004-1148-4.

References
1.
Treseler P, Sanfilippo F . Relative contribution of major histocompatibility complex antigens to the immunogenicity of corneal allografts. Transplantation. 1986; 41(4):508-14. DOI: 10.1097/00007890-198604000-00018. View

2.
Roy R, Boisjoly H, Wagner E, Langlois A, BERNARD P, Bazin R . Pretransplant and posttransplant antibodies in human corneal transplantation. Transplantation. 1992; 54(3):463-7. DOI: 10.1097/00007890-199209000-00015. View

3.
Zavazava N, Westphal E, Duncker G, Nolle B, Muller-Ruchholtz W . Post-mortem HLA tissue typing of retinal pigment epithelial cells. Scand J Immunol Suppl. 1992; 11:192-4. DOI: 10.1111/j.1365-3083.1992.tb01650.x. View

4.
Batchelor J, Casey T, WERB A, Gibbs D, Prasad S, Lloyd D . HLA matching and corneal grafting. Lancet. 1976; 1(7959):551-4. DOI: 10.1016/s0140-6736(76)90355-x. View

5.
. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol. 1992; 110(10):1392-403. View